Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCAS
NCT06040255Phase 4Enrolling by invitation
- Sponsor
- University of California, San Francisco
- Start
- Oct 2023
- Primary completion
- Jul 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of methylprednisolone, prednisolone, prednisone in focal cerebral arteriopathy (FCA), arterial ischemic stroke (AIS), Transient Ischemic Attack (TIA), sponsored by University of California, San Francisco. Started Oct 2023; status: enrolling by invitation.
02
Drugs
methylprednisoloneprednisoloneprednisone
03
Conditions
focal cerebral arteriopathy (FCA)arterial ischemic stroke (AIS)Transient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06040255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040255.